The global viscosity feed market is expected to reach USD 6.27 billion by 2028 according to the research. Patients with osteoarthritis have a minimally invasive treatment option called viscosity.
NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Viscosupplementation Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Inflation Impact, Opportunity Analysis for Company” – https https://www.reportlinker.com/p06381971/?utm_source=GNW
As viscosity increases, hyaluronic acid is pushed into the joints. The synovial fluid that covers the joints contains hyaluronic acid, which is a naturally occurring substance. It lubricates the joints to allow the bones to move freely and reduce discomfort. Hyaluronic acid levels in the joints are lower in people with osteoarthritis, which causes pain. According to our research findings, the worldwide viscosity market will reach USD 3.71 Billion in 2022.
The global viscosity market will grow at a CAGR of 9.14% during the forecast period:
Increase in the incidence of osteoporosis, rising geriatric population, and increase in the number of product launches and product approvals are some of the major factors driving the growth in size of the global viscosity supplement market. Arthritis is one of the most common types of arthritis. In 2019, the Centers for Disease Control and Prevention estimated that 32.5 million Americans (1 in 7 adults) had osteoporosis. Due to the increase in chronic diseases such as obesity, diabetes and heart disease, the prevalence of osteoporosis has reached alarming levels. In addition, lack of physical activity, such as aerobic exercise, increases the need for knee and hip osteoarthritis treatment and drives market expansion.
Single injection viscosity owns the lion’s share
By procedure, the viscosity market is divided into three segments, that is, single injection viscosity injection, three viscosity injection, and five viscosity injection. Among all, the current viscosity supplement market is dominated by single injections. Demand for outpatient surgeries providing same-day surgical care, including preventive (surgical) and diagnostic procedures, is driving the single injection segment. Further, the increase in product launches and focus on developing single injections for the treatment of osteoarthritis is expected to contribute to the significant growth of the single injection market over the forecast period.
By Application: Knee Osteoarthritis segment dominates the market share
Due to the increasing prevalence of knee osteoarthritis and the increasing number of elderly people, who are more susceptible to knee osteoarthritis, the knee osteoarthritis segment has dominated the viscoelastic market and is expected to maintain this trend during the forecast period. In addition, the effect of aging, which reduces the amount of water in the cartilage and reduces its ability to absorb shock and cushion, makes the elderly population more susceptible to knee osteoarthritis.
Orthopedic Clinics / Ambulatory Surgery Centers division is growing at a significant rate of growth
By end users, the Viscosupplementation market is segmented into hospitals and orthopedic clinics/ambulatory surgery centres. Outpatient service locations, particularly those providing ambulatory surgery and office treatments from physicians, have grown to be fierce competitors to hospitals due to the recent adoption of value-based care. Orthopedic clinics/ambulatory surgery centers offer practical and financial benefits, such as quick access to patients, affordable prices, more opportunities for physician involvement, and outpatient facilities. Hence they gain a dominant market share in the viscosity market.
By Region: North America and Asia Pacific have a significant market share
North America holds a dominant position in the global viscosity supplement market. Factors contributing to the growth of viscoelastic augmentation in the North American region are the increasing prevalence of osteoporosis and related diseases, older age, an established health care system, and a growing desire for non-surgical procedures. Moreover, the Asia Pacific region is expected to grow at a remarkable rate of growth over the forecast period due to the increase in the number of elderly people and the rise in healthcare expenditures.
Analysis of the main players
Anika Therapeutics Inc. Sanofi, Zimmer Biomet, Smith & Nephew PLC, Lifecore Biomedical, LG Life Sciences Ltd. and F.Hoffmann-La Roche Ltd. and Chugai Pharmaceutical Co., Ltd. are the leading companies in the global viscosity supplement market. These companies use a variety of business methods, including collaborations, product launches, approvals, and collaborations to maintain their position in the market.
Impact of Covid-19 on the global viscosity market
Viscous supplementation is a non-emergency procedure, hence during the COVID-19 pandemic, most procedures have been canceled or delayed. As a result, it has hindered market expansion and reduced demand for viscosity boosters. Additionally, the industry has suffered because older citizens—a population that has mostly been urged to stay home to reduce infection risk—consume the majority of viscosity supplement products. However, with the reduction of covid-19 restrictions, procedures have resumed, and patients have started visiting hospitals, the global viscosity supplement market has once again gained its potential.
This latest report “Global Viscosity Supplements Market Forecasts by Product (Single Viscosity Injection, Three Viscosity Injections and Five Viscosity Injections), by Application (Knee Osteoarthritis, Hip Osteoarthritis, Hand/Wrist Osteoarthritis, Ankle/Foot Osteoarthritis etc.) ), by end user (hospitals, mobile orthopedic clinics/surgical centers), by region (North America, Europe, Asia Pacific, ROW), principal factor analysis (Anika Therapeutics Inc., Sanofi, Zimmer Biomet, Smith & Nephew PLC , Lifecore Biomedical, LG Life Sciences Ltd., F.Hoffmann-La Roche Ltd. and Chugai Pharmaceutical Co.)” provide a detailed analysis of the global viscosity industry.
1. One time viscosity injection
2. Three viscosity injections
3. Five viscosity injections
1. Knee osteoarthritis
2. Hip osteoarthritis
3. Fragility of the hand / wrist
4. Ankle/foot osteoarthritis
2. Orthopedic clinics / ambulatory surgery centers
1. North America
3. Asia Pacific
4. The rest of the world
The main players
1. Anika Therapeutics Inc.
3. Zimmer Biomet
4. Smith Onview plc
5. The biomedical life cycle
6. LG Life Sciences Ltd.
7. F.Hoffmann-La Roche Ltd.
8. Chugai Pharmaceutical Co., Ltd.
Read the full report: https://www.reportlinker.com/p06381971/?
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001